B7-H3-targeted CAR-T cells

B7-H3-targeted CAR-T cells are an investigational class of adoptive cell therapies engineered to express chimeric antigen receptors (CARs) that specifically recognize CD276 (B7-H3), a member of the B7 family of immune checkpoint proteins. B7-H3 is highly overexpressed in a variety of solid tumors—including glioblastoma, neuroblastoma, and colorectal cancer—while maintaining low expression in normal tissues, making it an attractive target for cellular immunotherapy. Upon binding to B7-H3 on the tumor cell surface, these CAR-T cells are activated to proliferate and exert direct cytotoxic effects. Advanced iterations of this therapy, such as those being developed by Fuzhou Tcelltech, incorporate additional genetic modifications like the co-expression of 4-1BBL and OX40L fusion proteins to provide CAR-independent survival signals, thereby enhancing T-cell persistence, infiltration, and resistance to exhaustion within the immunosuppressive tumor microenvironment.

Other names

CD276-targeted CAR-T cellsCD-276-targeted CAR-T cellsCD 276-targeted CAR-T cellsB7-H3 CAR-TB-7-H3 CAR-TB 7-H3 CAR-T